These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

782 related articles for article (PubMed ID: 29176714)

  • 1. Analyses of gut microbiota and plasma bile acids enable stratification of patients for antidiabetic treatment.
    Gu Y; Wang X; Li J; Zhang Y; Zhong H; Liu R; Zhang D; Feng Q; Xie X; Hong J; Ren H; Liu W; Ma J; Su Q; Zhang H; Yang J; Wang X; Zhao X; Gu W; Bi Y; Peng Y; Xu X; Xia H; Li F; Xu X; Yang H; Xu G; Madsen L; Kristiansen K; Ning G; Wang W
    Nat Commun; 2017 Nov; 8(1):1785. PubMed ID: 29176714
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Acarbose treatment affects the serum levels of inflammatory cytokines and the gut content of bifidobacteria in Chinese patients with type 2 diabetes mellitus.
    Su B; Liu H; Li J; Sunli Y; Liu B; Liu D; Zhang P; Meng X
    J Diabetes; 2015 Sep; 7(5):729-39. PubMed ID: 25327485
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Habitual Dietary Intake Affects the Altered Pattern of Gut Microbiome by Acarbose in Patients with Type 2 Diabetes.
    Takewaki F; Nakajima H; Takewaki D; Hashimoto Y; Majima S; Okada H; Senmaru T; Ushigome E; Hamaguchi M; Yamazaki M; Tanaka Y; Nakajima S; Ohno H; Fukui M
    Nutrients; 2021 Jun; 13(6):. PubMed ID: 34205413
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effects of metformin, acarbose, and sitagliptin monotherapy on gut microbiota in Zucker diabetic fatty rats.
    Zhang M; Feng R; Yang M; Qian C; Wang Z; Liu W; Ma J
    BMJ Open Diabetes Res Care; 2019; 7(1):e000717. PubMed ID: 31641523
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effects of Non-insulin Anti-hyperglycemic Agents on Gut Microbiota: A Systematic Review on Human and Animal Studies.
    Cao TTB; Wu KC; Hsu JL; Chang CS; Chou C; Lin CY; Liao YM; Lin PC; Yang LY; Lin HW
    Front Endocrinol (Lausanne); 2020; 11():573891. PubMed ID: 33071980
    [No Abstract]   [Full Text] [Related]  

  • 6. Metagenomic analysis reveals crosstalk between gut microbiota and glucose-lowering drugs targeting the gastrointestinal tract in Chinese patients with type 2 diabetes: a 6 month, two-arm randomised trial.
    Zhang X; Ren H; Zhao C; Shi Z; Qiu L; Yang F; Zhou X; Han X; Wu K; Zhong H; Li Y; Li J; Ji L
    Diabetologia; 2022 Oct; 65(10):1613-1626. PubMed ID: 35930018
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comprehensive Analysis of Serum and Fecal Bile Acid Profiles and Interaction with Gut Microbiota in Primary Biliary Cholangitis.
    Chen W; Wei Y; Xiong A; Li Y; Guan H; Wang Q; Miao Q; Bian Z; Xiao X; Lian M; Zhang J; Li B; Cao Q; Fan Z; Zhang W; Qiu D; Fang J; Gershwin ME; Yang L; Tang R; Ma X
    Clin Rev Allergy Immunol; 2020 Feb; 58(1):25-38. PubMed ID: 30900136
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The Glucoamylase Inhibitor Acarbose Has a Diet-Dependent and Reversible Effect on the Murine Gut Microbiome.
    Baxter NT; Lesniak NA; Sinani H; Schloss PD; Koropatkin NM
    mSphere; 2019 Feb; 4(1):. PubMed ID: 30728281
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Unconjugated and secondary bile acid profiles in response to higher-fat, lower-carbohydrate diet and associated with related gut microbiota: A 6-month randomized controlled-feeding trial.
    Wan Y; Yuan J; Li J; Li H; Zhang J; Tang J; Ni Y; Huang T; Wang F; Zhao F; Li D
    Clin Nutr; 2020 Feb; 39(2):395-404. PubMed ID: 30876827
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Fasting and refeeding triggers specific changes in bile acid profiles and gut microbiota.
    Zhang Y; Qi H; Wang L; Hu C; Gao A; Wu Q; Wang Q; Lin H; Chen B; Wang X; Wang S; Lin H; Wang W; Bi Y; Wang J; Lu J; Liu R
    J Diabetes; 2023 Feb; 15(2):165-180. PubMed ID: 36682739
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Metformin Is Associated With Higher Relative Abundance of Mucin-Degrading Akkermansia muciniphila and Several Short-Chain Fatty Acid-Producing Microbiota in the Gut.
    de la Cuesta-Zuluaga J; Mueller NT; Corrales-Agudelo V; Velásquez-Mejía EP; Carmona JA; Abad JM; Escobar JS
    Diabetes Care; 2017 Jan; 40(1):54-62. PubMed ID: 27999002
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Response of gut microbiota in type 2 diabetes to hypoglycemic agents.
    Zhang F; Wang M; Yang J; Xu Q; Liang C; Chen B; Zhang J; Yang Y; Wang H; Shang Y; Wang Y; Mu X; Zhu D; Zhang C; Yao M; Zhang L
    Endocrine; 2019 Dec; 66(3):485-493. PubMed ID: 31410749
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Disentangling type 2 diabetes and metformin treatment signatures in the human gut microbiota.
    Forslund K; Hildebrand F; Nielsen T; Falony G; Le Chatelier E; Sunagawa S; Prifti E; Vieira-Silva S; Gudmundsdottir V; Pedersen HK; Arumugam M; Kristiansen K; Voigt AY; Vestergaard H; Hercog R; Costea PI; Kultima JR; Li J; Jørgensen T; Levenez F; Dore J; ; Nielsen HB; Brunak S; Raes J; Hansen T; Wang J; Ehrlich SD; Bork P; Pedersen O
    Nature; 2015 Dec; 528(7581):262-266. PubMed ID: 26633628
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The delayed effects of antibiotics in type 2 diabetes, friend or foe?
    Fu L; Qiu Y; Shen L; Cui C; Wang S; Wang S; Xie Y; Zhao X; Gao X; Ning G; Nie A; Gu Y
    J Endocrinol; 2018 Aug; 238(2):137-149. PubMed ID: 29929986
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The Relationship between Frequently Used Glucose-Lowering Agents and Gut Microbiota in Type 2 Diabetes Mellitus.
    Lv Y; Zhao X; Guo W; Gao Y; Yang S; Li Z; Wang G
    J Diabetes Res; 2018; 2018():1890978. PubMed ID: 29854817
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Analysis of metabolome changes in the bile acid pool in feces and plasma of antibiotic-treated rats.
    Behr C; Slopianka M; Haake V; Strauss V; Sperber S; Kamp H; Walk T; Beekmann K; Rietjens IMCM; van Ravenzwaay B
    Toxicol Appl Pharmacol; 2019 Jan; 363():79-87. PubMed ID: 30502395
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comprehensive relationships between gut microbiome and faecal metabolome in individuals with type 2 diabetes and its complications.
    Zhao L; Lou H; Peng Y; Chen S; Zhang Y; Li X
    Endocrine; 2019 Dec; 66(3):526-537. PubMed ID: 31591683
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The association of type II diabetes with gut microbiota composition.
    Navab-Moghadam F; Sedighi M; Khamseh ME; Alaei-Shahmiri F; Talebi M; Razavi S; Amirmozafari N
    Microb Pathog; 2017 Sep; 110():630-636. PubMed ID: 28739439
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Gut microbiota in patients with COVID-19 and type 2 diabetes: A culture-based method.
    Petakh P; Kobyliak N; Kamyshnyi A
    Front Cell Infect Microbiol; 2023; 13():1142578. PubMed ID: 36844398
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Dose-response effect of berberine on bile acid profile and gut microbiota in mice.
    Guo Y; Zhang Y; Huang W; Selwyn FP; Klaassen CD
    BMC Complement Altern Med; 2016 Oct; 16(1):394. PubMed ID: 27756364
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 40.